SNPs associated with thalidomide-related peripheral neuropathy
| SNP (rs#) . | Gene . | Location . | Base change . | Genotype and distribution . | Treatment . | Observation . | P-value interaction . | ||
|---|---|---|---|---|---|---|---|---|---|
| HR . | 95% CI . | HR . | 95% CI . | ||||||
| rs11552449 | DCLRE1B | Exon | C>T | TT/TC/CC (5/49/133) | 0.64 | 0.33-1.27 | 3.11 | 1.01-9.57 | .010 |
| rs37973 | GLCCI1 | 5′UTR | A>G | GG/GA/AA (35/93/56) | 0.51 | 0.28-0.91 | 4.03 | 0.52-31.10 | .046 |
| SNP (rs#) . | Gene . | Location . | Base change . | Genotype and distribution . | Treatment . | Observation . | P-value interaction . | ||
|---|---|---|---|---|---|---|---|---|---|
| HR . | 95% CI . | HR . | 95% CI . | ||||||
| rs11552449 | DCLRE1B | Exon | C>T | TT/TC/CC (5/49/133) | 0.64 | 0.33-1.27 | 3.11 | 1.01-9.57 | .010 |
| rs37973 | GLCCI1 | 5′UTR | A>G | GG/GA/AA (35/93/56) | 0.51 | 0.28-0.91 | 4.03 | 0.52-31.10 | .046 |
HR represents hazard of patients with at least 1 minor allele vs patients with 2 major alleles.
Abbreviations are explained in Table 1.